To the full analysis
Novanta stock: growth
NOVTNovanta reported $980.6M in revenue for fiscal 2025, up 3.3% on the prior year, up 10.7% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
6.2%
per year from 2006 to 2025, per share 0.9%
Earnings (Annual rate)
4.9%
per year from 2006 to 2025, per share −0.3%
Free cash flow (Annual rate)
3.2%
per year from 2006 to 2025, per share −1.9%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 10.7% | 10.1% | 6.2% |
| Revenue per share | 9.8% | 9.5% | 0.9% |
| Earnings | 3.9% | 4.2% | 4.9% |
| Earnings per share | 3.0% | 3.6% | −0.3% |
| Free cash flow | −17.9% | 5.7% | 3.2% |
| Free cash flow per share | −18.5% | 5.1% | −1.9% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $313.61M | $21.74M | $26.69M |
| 2007 | $291.08M | $15.16M | $32.95M |
| 2008 | $288.47M | −$203.85M | −$334.73M |
| 2009 | $254.39M | −$71.33M | −$27.11M |
| 2010 | $383.52M | −$687K | −$7.4M |
| 2011 | $366.28M | $28.97M | $40.96M |
| 2012 | $271.5M | $19.54M | $24.12M |
| 2013 | $341.61M | $7.31M | $44.21M |
| 2014 | $364.71M | −$24.25M | $36.87M |
| 2015 | $373.6M | $35.62M | $27.86M |
| 2016 | $384.76M | $22M | $39.33M |
| 2017 | $521.29M | $60.05M | $54.28M |
| 2018 | $614.34M | $49.11M | $74.99M |
| 2019 | $626.1M | $40.77M | $52.51M |
| 2020 | $590.62M | $44.52M | $129.72M |
| 2021 | $706.79M | $50.33M | $72.45M |
| 2022 | $860.9M | $74.05M | $71.14M |
| 2023 | $881.66M | $72.88M | $100.11M |
| 2024 | $949.25M | $64.09M | $141.35M |
| 2025 | $980.6M | $53.83M | $48.43M |
Revenue by segment
How Novanta Inc. makes its money and how that has shifted. Names are as the company reports them.
- Robotics and Automation32%
- Advanced Surgery25%
- Precision Medicine24%
- Precision Manufacturing19%
Figures as a table
| 2024 | 2025 | Share 2025 | |
|---|---|---|---|
| Robotics and Automation | $288.32M | $318.58M | 32.5% |
| Advanced Surgery | $208.75M | $242.44M | 24.7% |
| Precision Medicine | $249.87M | $237.32M | 24.2% |
| Precision Manufacturing | $202.3M | $182.26M | 18.6% |
| Total revenue | $949.25M | $980.6M | 100% |
Revenue by region
Where Novanta Inc. generates its revenue.
- United States53%
- Rest Of Europe14%
- Germany12%
- Rest of Asia Pacific10%
- China10%
- Other2%
“Other” combines smaller regions with revenue the company does not assign to a region.
Figures as a table
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $154.76M | $220.58M | $242.24M | $254.28M | $225.76M | $270.83M | $372.35M | $418.27M | $487.11M | $519.01M | 52.9% |
| Rest Of Europe | $51.71M | $81M | $105.61M | $129.64M | $127.04M | $138.86M | $137.8M | $137.03M | $128.87M | $137.41M | 14% |
| Germany | $55.94M | $68M | $88.03M | $82.03M | $83.77M | $101.87M | $133.73M | $128.23M | $123.24M | $114.65M | 11.7% |
| Rest of Asia Pacific | $60.1M | $84.73M | $104.3M | $89.59M | $74.33M | $89.2M | $101.6M | $105.35M | $107.05M | $97.03M | 9.9% |
| China | $44.23M | $56.13M | $66.41M | $59.51M | $70.56M | $95.05M | $97.18M | $73.44M | $84.56M | $93.2M | 9.5% |
| Other | $18.03M | $10.85M | $7.75M | $11.05M | $9.17M | $10.99M | $18.25M | $19.35M | $18.4M | $19.31M | 2% |
| Total revenue | $384.76M | $521.29M | $614.34M | $626.1M | $590.62M | $706.79M | $860.9M | $881.66M | $949.25M | $980.6M | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak since 11 Nov 2026, previously Neutral
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.